The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has placed a global public burden on health authorities. Although the virological characteristics and pathogenesis of COVID-19 has been largely clarified, there is currently no specific therapeutic measure. In severe cases, acute SARS-CoV-2 infection leads to immune disorders and damage to both the adaptive and innate immune responses. Having roles in immune regulation and regeneration, mesenchymal stem cells (MSCs) serving as a therapeutic option may regulate the over-activated inflammatory response and promote recovery of lung damage. Since the outbreak of the COVID-19 pandemic, a series of MSC-therapy clinical trials has been conducted. The findings indicate that MSC treatment not only significantly reduces lung damage, but also improves patient recovery with safety and good immune tolerance. Herein, we summarize the recent progress in MSC therapy for COVID-19 and highlight the challenges in the field.
【저자키워드】 Infectious diseases, Stem-cell research, 【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, coronavirus, clinical trial, adaptive, COVID-19 pandemic, immune regulation, MSCs, Characteristics, outbreak, therapeutic, Patient, severe cases, immune disorder, Inflammatory response, regulate, MSC, therapeutic option, lung damage, stem cell, health authorities, MSC therapy, acute respiratory syndrome, Virological, immune tolerance, pathogenesis of COVID-19, acute SARS-CoV-2 infection, innate immune responses, highlight, IMPROVE, caused, significantly, conducted, promote, reduce, 【제목키워드】 therapy, severe COVID-19, mesenchymal stem cell,